Patents matching “antagonist”

US 8207170

Heterocyclic substituted piperazines with CXCR3 antagonist activity

Pharmacopeia Drug Discovery, Inc. · Granted Jun 26, 2012 · Expires Jun 21, 2032

US 8202891

Quaternary ammonium compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jun 19, 2012 · Expires Jun 14, 2032

US 8198304

Guanidine-containing compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jun 12, 2012 · Expires Jun 7, 2032

US 8173815

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted May 8, 2012 · Expires May 3, 2032

US 8168678

N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

Panmira Pharmaceuticals, LLC · Granted May 1, 2012 · Expires Apr 26, 2032

US 8163737

CGRP receptor antagonists

Vertex Pharmaceuticals Incorporated · Granted Apr 24, 2012 · Expires Apr 19, 2032

US 8163805

Small molecule antagonists of Bcl-2 family proteins

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 24, 2012 · Expires Apr 19, 2032

US 8153781

Dendrimer conjugates of agonists and antagonists of the GPCR superfamily

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 10, 2012 · Expires Apr 5, 2032

US 8153686

Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

Theravance, Inc. · Granted Apr 10, 2012 · Expires Apr 5, 2032

US 8143226

Tyrosine kinase receptor antagonists and methods of treatment for breast cancer

The Regents of the University of California · Granted Mar 27, 2012 · Expires Mar 22, 2032

US 8143277

Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Theravance, Inc. · Granted Mar 27, 2012 · Expires Mar 22, 2032

US 8138345

Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

Theravance, Inc. · Granted Mar 20, 2012 · Expires Mar 15, 2032

US 8138216

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Mar 20, 2012 · Expires Mar 15, 2032

US 8133905

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Mar 13, 2012 · Expires Mar 8, 2032

US 8134006

Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Theravance, Inc. · Granted Mar 13, 2012 · Expires Mar 8, 2032

US 8133904

Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

Jenrin Discovery, LLC · Granted Mar 13, 2012 · Expires Mar 8, 2032

US 8124627

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Feb 28, 2012 · Expires Feb 23, 2032

US 8119796

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Feb 21, 2012 · Expires Feb 16, 2032

US 8114394

Use of IL-1 antagonists to treat gout

REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2012 · Expires Feb 9, 2032

US 8110546

VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Feb 7, 2012 · Expires Feb 2, 2032

US 8106232

3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

Theravance, Inc. · Granted Jan 31, 2012 · Expires Jan 26, 2032

US 8101791

Aminotetralin compounds as mu opioid receptor antagonists

Theravance, Inc. · Granted Jan 24, 2012 · Expires Jan 19, 2032

US 8092803

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2012 · Expires Jan 5, 2032

US 8088798

Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

Jensen Discovery, Inc. · Granted Jan 3, 2012 · Expires Dec 29, 2031